Mint Tower Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mint Tower Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-59	Closed	-$37K	–	394
2021 Q4	$37K	Buy	+59	New	+$36.3K	﹤0.01%	325
2019 Q3	–	Sell	-4,838	Closed	-$1.51M	–	239
2019 Q2	$1.51M	Buy	4,838 +4,670	+2,780%	+$1.55M	0.16%	135
2019 Q1	$69K	Buy	+168	New	+$69.2K	0.01%	161

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mint Tower Capital Management's REGN Position: Q1 2022 in Review

Mint Tower Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 59 shares — an estimated $37K sold.

Mint Tower Capital Management first reported a position in REGN in Q1 2019 and held it in 3 quarters. The position peaked at $1.51M in Q2 2019. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Mint Tower Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Mint Tower Capital Management sold 59 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $37K.
Mint Tower Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 3 quarters.
Mint Tower Capital Management's Regeneron Pharmaceuticals position peaked at $1.51M in Q2 2019.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Mint Tower Capital Management's 13F filing for Q1 2022, filed 29 Apr 2022.